bleeding

(redirected from clinically significant bleeding)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

bleeding

[′blēd·iŋ]
(chemical engineering)
The undesirable movement of certain components of a plastic material to the surface of a finished article. Also known as migration.
(engineering)
Natural separation of a liquid from a liquid-solid or semisolid mixture; for example, separation of oil from a stored lubricating grease, or water from freshly poured concrete. Also known as bleedout.
(materials)
The outward penetration of a coloring agent from a substrate through the surface coat of paint.
The movement of grout through a pavement from below a road surfacing material to the outer surface.
(textiles)
Referring to a fabric in which the dye is not fast and therefore comes out when the fabric is wet.

bleeding

1. The upward penetration of a coloring pigment from a substrate through a topcoat of paint.
2. The oozing of grout from below a road-surfacing material to the surface in hot weather.
3. Exudation of one or more components of a sealant, with possible absorption by adjacent porous surfaces.
4. The autogenous flow of mixing water within, or its emergence from, newly placed concrete or mortar; caused by the settlement of the solid materials within the mass or by drainage of mixing water; also called water gain.
5. The diffusion of coloring matter through a coating from the substrate, or the discoloration that arises from such a process.
References in periodicals archive ?
The study will evaluate the standard clinical endpoints of death, myocardial infarction, revascularization and clinically significant bleeding at 30-days.
Results showed that that treatment with rNAPc2, in addition to standard antithrombotic therapies in patients with ACS, resulted in a dose-related inhibition of thrombin generation without an increase in clinically significant bleeding.
Clinical endpoints will be the occurrence of clinically significant bleeding and gastric pH levels, plus safety and tolerability.
The prolongation of bleeding time reported in these studies has not exceeded normal limits and did not produce clinically significant bleeding episodes.
22% reduction in death, myocardial infarction (MI), revascularization or clinically significant bleeding (TIMI-major and minor bleeding or transfusions).
Combined rates of clinically significant bleeding (TIMI major or minor bleeding) in the as-treated population were 3.
Phase II clinical trials are currently underway to evaluate IPMs ability to control hemorrhage in thrombocytopenic patients with clinically significant bleeding.

Full browser ?